{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:42:33Z","timestamp":1785469353293,"version":"3.56.0"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) represents a major advance for the development of human disease models. The emerging of this technique fostered the concept of \u201cdisease in a dish,\u201d which consists into the generation of patient-specific models<jats:italic>in vitro<\/jats:italic>. Currently, iPSCs are used to study pathological molecular mechanisms caused by genetic mutations and they are considered a reliable model for high-throughput drug screenings. Importantly, precision-medicine approaches to treat monogenic disorders exploit iPSCs potential for the selection and validation of lead candidates. For example, antisense oligonucleotides (ASOs) were tested with promising results in myoblasts or motor neurons differentiated from iPSCs of patients affected by either Duchenne muscular dystrophy or Amyotrophic lateral sclerosis. However, the use of iPSCs needs additional optimization to ensure translational success of the innovative strategies based on gene delivery through adeno associated viral vectors (AAV) for these diseases. Indeed, to establish an efficient transduction of iPSCs with AAV, several aspects should be optimized, including viral vector serotype, viral concentration and timing of transduction. This review will outline the use of iPSCs as a model for the development and testing of gene therapies for neuromuscular and motor neuron disorders. It will then discuss the advantages for the use of this versatile tool for gene therapy, along with the challenges associated with the viral vector transduction of iPSCs.<\/jats:p>","DOI":"10.3389\/fcell.2021.662837","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T11:12:54Z","timestamp":1618398774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders"],"prefix":"10.3389","volume":"9","author":[{"given":"Marisa","family":"Cappella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Elouej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Biferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides.","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"B2","article-title":"Cell-based therapies for amyotrophic lateral sclerosis\/motor neuron disease.","volume":"12","author":"Abdul Wahid","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1523\/jneurosci.0906-12.2013","article-title":"Accelerated high-yield generation of limb-innervating motor neurons from human stem cells.","volume":"33","author":"Amoroso","year":"2013","journal-title":"J. Neurosci."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cell.2020.11.017","article-title":"Generation of functional human 3D cortico-motor assembloids.","volume":"183","author":"Andersen","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74346-9","article-title":"Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.","volume":"10","author":"Ando","year":"2020","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2011.255","article-title":"Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells.","volume":"20","author":"Asuri","year":"2012","journal-title":"Mol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for Duchenne muscular dystrophy.","volume":"28","author":"Barth\u00e9l\u00e9my","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin 2 extends lifespan and reduces pathology in TDP-43 mice.","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12015-018-9811-3","article-title":"Genome editing in induced pluripotent stem cells using CRISPR\/Cas9.","volume":"14","author":"Ben Jehuda","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs.","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.ymthe.2020.05.011","article-title":"AAV9-mediated expression of SMN restricted to neurons does not rescue the spinal muscular atrophy phenotype in mice.","volume":"28","author":"Besse","year":"2020","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model.","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ebiom.2019.11.026","article-title":"Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity.","volume":"50","author":"Birger","year":"2019","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1073\/pnas.80.15.4856","article-title":"Defective myoblasts identified in Duchenne muscular dystrophy.","volume":"80","author":"Blau","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member.","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS\u2014a perspective.","volume":"20","author":"Cappella","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/jnd-200531","article-title":"Beyond the traditional clinical trials for amyotrophic lateral sclerosis and the future impact of gene therapy.","volume":"8","author":"Cappella","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-020-00224-7","article-title":"Acute conversion of patient-derived Duchenne muscular dystrophy iPSC into myotubes reveals constitutive and inducible over-activation of TGF\u03b2-dependent pro-fibrotic signaling.","volume":"10","author":"Caputo","year":"2020","journal-title":"Skelet. Muscle"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/nprot.2016.110","article-title":"Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro.","volume":"11","author":"Chal","year":"2016","journal-title":"Nat. Protoc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems.","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/mt.2016.84","article-title":"In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy.","volume":"24","author":"Choudhury","year":"2016","journal-title":"Mol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy.","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate pompe mice.","volume":"12","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111438","article-title":"iPSCs-based neural 3D systems: a multidimensional approach for disease modeling and drug discovery.","volume":"8","author":"Costamagna","year":"2019","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides.","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics.","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metabol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1093\/hmg\/ddz128","article-title":"AAV-based gene therapies for the muscular dystrophies.","volume":"28","author":"Crudele","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.stemcr.2020.03.023","article-title":"Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS\/FTD.","volume":"14","author":"Dafinca","year":"2020","journal-title":"Stem Cell Reports"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/stem.2388","article-title":"C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia.","volume":"34","author":"Dafinca","year":"2016","journal-title":"Stem Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cells7120253","article-title":"Induced pluripotent stem cells for Duchenne muscular Dystrophy modeling and therapy.","volume":"7","author":"Danisovic","year":"2018","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases.","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.scr.2015.07.005","article-title":"Formation and characterisation of neuromuscular junctions between hiPSC derived motoneurons and myotubes.","volume":"15","author":"Demestre","year":"2015","journal-title":"Stem Cell Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.omtm.2020.05.028","article-title":"Cerebral organoids: a human model for AAV capsid selection and therapeutic transgene efficacy in the brain.","volume":"18","author":"Depla","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval.","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1089\/scd.2013.0135","article-title":"Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations.","volume":"22","author":"Dick","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.1158799","article-title":"Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.","volume":"321","author":"Dimos","year":"2008","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention.","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050403","article-title":"Current challenges of iPSC-based disease modeling and therapeutic implications.","volume":"8","author":"Doss","year":"2019","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1093\/hmg\/ddt386","article-title":"Length-dependent CTG\u22c5CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells.","volume":"22","author":"Du","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy.","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7281912","article-title":"Comparative AAV-eGFP transgene expression using vector serotypes 1\u20139, 7m8, and 8b in human pluripotent stem cells, RPEs, and human and rat cortical neurons (Hindawi).","volume":"2019","author":"Duong","year":"2019","journal-title":"Stem Cells Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","article-title":"Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent.","volume":"24","author":"Fujimori","year":"2018","journal-title":"Nat. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: structure, function and implications for therapy.","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7866","article-title":"Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.","volume":"9","author":"Gendron","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.037424","article-title":"Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis.","volume":"12","author":"Giorgio","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1038\/srep42367","article-title":"Rapid differentiation of human pluripotent stem cells into functional neurons by mRNAs encoding transcription factors.","volume":"7","author":"Goparaju","year":"2017","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1089\/hum.2018.234","article-title":"Five years of successful inducible transgene expression following locoregional adeno-associated virus delivery in nonhuman primates with no detectable immunity.","volume":"30","author":"Guilbaud","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","article-title":"Selection of an efficient AAV vector for robust CNS transgene expression.","volume":"15","author":"Hanlon","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1536\/ihj.15-376","article-title":"Generation of induced pluripotent stem cells from patients with Duchenne muscular dystrophy and their induction to cardiomyocytes.","volume":"57","author":"Hashimoto","year":"2016","journal-title":"Int. Heart J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/156652309789753383","article-title":"AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS.","volume":"9","author":"Hester","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00164","article-title":"Genetically-informed patient selection for iPSC studies of complex diseases may aid in reducing cellular heterogeneity.","volume":"11","author":"Hoekstra","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1081-0","article-title":"Cell cycle inhibitors protect motor neurons in an organoid model of spinal muscular atrophy.","volume":"9","author":"Hor","year":"2018","journal-title":"Cell Death Dis."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00664-0","article-title":"ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation.","author":"Hor","year":"2020","journal-title":"Cell Death Differ."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cells5040046","article-title":"Translational prospects and challenges in human induced pluripotent stem cell research in drug discovery.","volume":"5","author":"Hosoya","year":"2016","journal-title":"Cells"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/mt.2010.287","article-title":"An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.","volume":"19","author":"Jang","year":"2011","journal-title":"Mol. Ther."},{"key":"B60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00039.2017","article-title":"Induced pluripotent stem cells and their use in human models of disease and development.","volume":"99","author":"Karagiannis","year":"2018","journal-title":"Physiol. Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/mt.2010.55","article-title":"Engineering of human pluripotent stem cells by AAV-mediated gene targeting.","volume":"18","author":"Khan","year":"2010","journal-title":"Mol. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.stem.2014.03.004","article-title":"Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1.","volume":"14","author":"Kiskinis","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bmcl.2017.06.027","article-title":"Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: screening with iPSC-derived neuronal cells.","volume":"27","author":"Lai","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene.","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","article-title":"Advances in pluripotent stem cells: history, mechanisms, technologies, and applications.","volume":"16","author":"Liu","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10048-015-0448-y","article-title":"The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation.","volume":"16","author":"Liu","year":"2015","journal-title":"Neurogenetics"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1186\/s13041-017-0300-4","article-title":"Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms.","volume":"10","author":"Madill","year":"2017","journal-title":"Mol. Brain"},{"key":"B69","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","article-title":"Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering.","volume":"23","author":"Maffioletti","year":"2018","journal-title":"Cell Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nprot.2013.019","article-title":"Reprogramming human fibroblasts to pluripotency using modified mRNA.","volume":"8","author":"Mandal","year":"2013","journal-title":"Nat. Protoc."},{"key":"B71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy.","volume":"16","author":"Martier","year":"","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B72","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","article-title":"Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients.","volume":"14","author":"Martier","year":"","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.3049","article-title":"Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes.","volume":"33","author":"Maury","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy.","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"B75","article-title":"Antisense oligonucleotides: treatment strategies and cellular internalization.","volume":"3","author":"Miller","year":"2016","journal-title":"RNA Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.bbrc.2009.08.075","article-title":"Gene targeting in human pluripotent stem cells with adeno-associated virus vectors.","volume":"388","author":"Mitsui","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.034728","article-title":"Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery.","volume":"11","author":"Mondragon-Gonzalez","year":"2018","journal-title":"Dis. Model Mech."},{"key":"B78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.reth.2019.07.002","article-title":"Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis \u2013 protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I\/IIa clinical trial (ROPALS trial).","volume":"11","author":"Morimoto","year":"2019","journal-title":"Regen. Ther."},{"key":"B79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS.","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"B81","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy.","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"B82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41434-020-0169-1","article-title":"Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters.","volume":"28","author":"Nieuwenhuis","year":"2020","journal-title":"Gene Ther."},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1038\/srep11746","article-title":"Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches.","volume":"5","author":"Nizzardo","year":"2015","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.1038\/srep21301","article-title":"Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype.","volume":"6","author":"Nizzardo","year":"2016","journal-title":"Sci. Rep."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204659","article-title":"Modified nucleic acids: expanding the capabilities of functional oligonucleotides.","volume":"25","author":"Ochoa","year":"2020","journal-title":"Molecules"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010020","article-title":"iPSCs as a platform for disease modeling, drug screening, and personalized therapy in muscular dystrophies.","volume":"8","author":"Ortiz-Vitali","year":"2019","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/mt.2016.145","article-title":"Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy.","volume":"24","author":"Osman","year":"2016","journal-title":"Mol. Ther."},{"key":"B88","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","article-title":"Disease-specific induced pluripotent stem (iPS) cells.","volume":"134","author":"Park","year":"","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nature06534","article-title":"Reprogramming of human somatic cells to pluripotency with defined factors.","volume":"451","author":"Park","year":"","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2020.09.013","article-title":"Towards advanced iPSC-based drug development for neurodegenerative disease.","volume":"27","author":"Pasteuning-Vuhman","year":"2020","journal-title":"Trends Mol. Med."},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-016-0340-5","article-title":"From animal models to human disease: a genetic approach for personalized medicine in ALS.","volume":"4","author":"Picher-Martel","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419833478","article-title":"Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies.","volume":"12","author":"Piga","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010167","article-title":"Investigation of new morpholino oligomers to increase survival motor neuron protein levels in spinal muscular atrophy.","volume":"19","author":"Ramirez","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.67","article-title":"Effectiveness of gene delivery systems for pluripotent and differentiated cells.","volume":"2","author":"Rapti","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B96","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA).","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"B97","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1021\/acs.jmedchem.6b00459","article-title":"Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy.","volume":"59","author":"Ratni","year":"2016","journal-title":"J. Med. Chem."},{"key":"B98","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/s0531-5565(00)00151-0","article-title":"Skeletal muscle regeneration and the mitotic clock.","volume":"35","author":"Renault","year":"2000","journal-title":"Exp. Gerontol."},{"key":"B99","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1358\/dnp.2008.21.8.1272126","article-title":"Artificial reprogramming of human somatic cells to generate pluripotent stem cells: a possible alternative to the controversial use of human embryonic stem cells.","volume":"21","author":"Romano","year":"2008","journal-title":"Drug News Perspect."},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9451492","article-title":"Pluripotent stem cells: current understanding and future directions.","volume":"2016","author":"Romito","year":"2016","journal-title":"Stem Cells Int."},{"key":"B101","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs.","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B102","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nn.4273","article-title":"Modeling ALS with motor neurons derived from human induced pluripotent stem cells.","volume":"19","author":"Sances","year":"2016","journal-title":"Nat. Neurosci."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14712598.2021.1832462","article-title":"Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy.","volume":"21","author":"Schneider","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases.","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"B106","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14712590903455989","article-title":"Gene-delivery systems for iPS cell generation.","volume":"10","author":"Shao","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress.","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1038\/srep12831","article-title":"Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.","volume":"5","author":"Shoji","year":"2015","journal-title":"Sci. Rep."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030075","article-title":"The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment.","volume":"10","author":"Smeriglio","year":"2020","journal-title":"J. Pers. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/153623003321512166","article-title":"Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors.","volume":"5","author":"Smith-Arica","year":"2003","journal-title":"Cloning Stem Cells"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.1227682","article-title":"iPSC disease modeling.","volume":"338","author":"Soldner","year":"2012","journal-title":"Science"},{"key":"B112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.stem.2011.07.014","article-title":"Conversion of mouse and human fibroblasts into functional spinal motor neurons.","volume":"9","author":"Son","year":"2011","journal-title":"Cell Stem Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice.","volume":"24","author":"Stein","year":"2016","journal-title":"Mol. Ther."},{"key":"B114","article-title":"Duchenne muscular dystrophy hiPSC\u2013derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice.","volume":"5","author":"Sun","year":"2020","journal-title":"JCI Insight"},{"key":"B115","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors.","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay2069","article-title":"Wrangling RNA: antisense oligonucleotides for neurological disorders.","volume":"11","author":"Talbot","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003541","article-title":"Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy.","volume":"4","author":"Tedesco","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.nbd.2015.06.011","article-title":"Modeling amyotrophic lateral sclerosis in pure human iPSc-derived motor neurons isolated by a novel FACS double selection technique.","volume":"82","author":"Toli","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"B119","doi-asserted-by":"crossref","DOI":"10.1038\/srep42522","article-title":"Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability.","volume":"7","author":"Ueki","year":"2017","journal-title":"Sci. Rep."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.043562","article-title":"Mouse models for muscular dystrophies: an overview.","volume":"13","author":"van Putten","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"B121","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy \u2013 a literature review.","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.042317","article-title":"Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility.","volume":"13","author":"Volpato","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","article-title":"Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.","volume":"7","author":"Wainger","year":"2014","journal-title":"Cell Rep."},{"key":"B124","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","article-title":"Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial.","volume":"78","author":"Wainger","year":"2020","journal-title":"JAMA Neurol."},{"key":"B125","first-page":"151","article-title":"STATE-of-the-art human gene therapy: part II. Gene therapy strategies and applications.","volume":"18","author":"Wang","year":"2014","journal-title":"Discov. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.stem.2010.08.012","article-title":"Highly efficient reprogramming to pluripotency and directed differentiation of human cells using synthetic modified mRNA.","volume":"7","author":"Warren","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B127","doi-asserted-by":"crossref","DOI":"10.1038\/srep00657","article-title":"Feeder-free derivation of human induced pluripotent stem cells with messenger RNA.","volume":"2","author":"Warren","year":"2012","journal-title":"Sci. Rep."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.035774","article-title":"Tracking progress: an update on animal models for Duchenne muscular dystrophy.","volume":"11","author":"Wells","year":"2018","journal-title":"Dis. Model Mech."},{"key":"B129","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/hum.2019.264","article-title":"High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction.","volume":"31","author":"Westhaus","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution.","author":"Wirth","year":"2021","journal-title":"Trends Neurosci."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders.","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B132","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/cell.2012.0086","article-title":"Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.","volume":"15","author":"Xia","year":"2013","journal-title":"Cell. Reprogram."},{"key":"B133","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40778-018-0145-5","article-title":"Human iPSC models to study orphan diseases: muscular dystrophies.","volume":"4","author":"Xia","year":"2018","journal-title":"Curr. Stem Cell Rep."},{"key":"B134","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.stem.2013.06.001","article-title":"Efficient generation of human iPS cells by a synthetic self-replicative RNA.","volume":"13","author":"Yoshioka","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B135","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells.","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"B136","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2018.03.025","article-title":"Stress granule assembly disrupts nucleocytoplasmic transport.","volume":"173","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/glia.23761","article-title":"Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology.","volume":"68","author":"Zhao","year":"2020","journal-title":"Glia"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.662837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:48:03Z","timestamp":1698893283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.662837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":137,"alternative-id":["10.3389\/fcell.2021.662837"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.662837","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"article-number":"662837"}}